Novel hydrophobically modified asymmetric RNAi compounds (sd-rxRNA) demonstrate robust efficacy in the eye.

Byrne, Michael; Tzekov, Radouil; Wang, Yi; Rodgers, Amanda; Cardia, James; Ford, Glenna; Holton, Katherine; Pandarinathan, Lakshmipathi; Lapierre, Jennifer; Stanney, William; Bulock, Karen; Shaw, Sharon; Libertine, Lyn; Fettes, Kevin; Khvorova, Anastasia; Kaushal, Shalesh; Pavco, Pamela

Byrne, Michael; Tzekov, Radouil; Wang, Yi; Rodgers, Amanda; Cardia, James; Ford, Glenna; Holton, Katherine; Pandarinathan, Lakshmipathi; Lapierre, Jennifer; Stanney, William; Bulock, Karen; Shaw, Sharon; Libertine, Lyn; Fettes, Kevin; Khvorova, Anastasia; Kaushal, Shalesh; Pavco, Pamela.

Affiliation

Byrne M; 1 RXi Pharmaceuticals, Corp. , Westborough, Massachusetts.

J Ocul Pharmacol Ther ; 29(10): 855-64, 2013 Dec.

Article in En | MEDLINE | ID: mdl-24180627

Subject(s)

RNA Interference; RNA, Small Interfering/administration & dosage; Retina/metabolism; Retinal Pigment Epithelium/metabolism; Animals; Cell Line; Eye Diseases/therapy; Humans; Hydrophobic and Hydrophilic Interactions; Intravitreal Injections; Mice; Mice, Inbred C57BL; RNA, Messenger/metabolism; Rabbits; Time Factors

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Retina / RNA, Small Interfering / RNA Interference / Retinal Pigment Epithelium Type of study: Prognostic_studies Limits: Animals / Humans Language: En Journal: J Ocul Pharmacol Ther Journal subject: FARMACOLOGIA / OFTALMOLOGIA / TERAPEUTICA Year: 2013 Type: Article

Fulltext

XML

PubMed Links

Search on Google